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Abstract During recent decades, Bangladesh has experi-
enced a rapid epidemiological transition from communicable
to non-communicable diseases. Coronary heart disease
(CHD), with myocardial infarction (MI) as its main
manifestation, is a major cause of death in the country.
However, there is limited reliable evidence about its deter-
minants in this population. The Bangladesh Risk of Acute
Vascular Events (BRAVE) study is an epidemiological
bioresource established to examine environmental, genetic,
lifestyle and biochemical determinants of CHD among the
Bangladeshi population. By early 2015, the ongoing BRAVE
study had recruited over 5000 confirmed first-ever MI cases,
and over 5000 controls ‘‘frequency-matched’’ by age and sex.
For each participant, information has been recorded on de-
mographic factors, lifestyle, socioeconomic, clinical, and
anthropometric characteristics. A 12-lead electrocardiogram
has been recorded. Biological samples have been collected
and stored, including extracted DNA, plasma, serum and
whole blood. Additionally, for the 3000 cases and 3000
controls initially recruited, genotyping has been done using
the CardioMetabochip? and the Exome? arrays. The mean
age (standard deviation) of MI cases is 53 (10) years, with
88 % of cases being male and 46 % aged 50 years or
younger. The median interval between reported onset of
symptoms and hospital admission is 5 h. Initial analyses
indicate that Bangladeshis are genetically distinct frommajor
non-SouthAsian ethnicities, aswell as distinct fromother South
Asian ethnicities. The BRAVE study is well-placed to serve as a
powerful resource to investigate current and future hypotheses
relating to environmental, biochemical and genetic causes of
CHD in an important but under-studied South Asian population.
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Introduction
Coronary heart disease (CHD), of which myocardial in-
farction (MI) is an important manifestation, remains the
single leading cause of death worldwide [1]. The majority
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of premature CHD deaths now occur in low- and middle-
income countries [1–3]. In particular, South Asia has
recorded the highest number of life-years lost due to pre-
mature CHD, a situation which reflects both the region’s
large population and the relatively young age at which
CHD death occurs in this population [4]. Furthermore,
while age-standardised CHD mortality rates have de-
creased during recent decades in many high-income
countries, they have continued to increase in South Asia
[5]. Nevertheless, there is limited evidence available about
the determinants of CHD in South Asia, even though it
could contribute importantly to scientific understanding
and to the development of appropriate strategies for the
prevention and control of CHD [6].
Bangladesh has experienced steep and sustained in-
creases in the incidence of CHD and other cardiovascular
conditions during recent decades [7]. Bangladesh is a
country with a population of over 160 million [8], yet it is
one of least studied major countries with regard to car-
diovascular disease [9]. The burden of CHD in Banglade-
shis is not just of local public health concern. For example,
CHD mortality has been reported to be more than two
times higher among Bangladeshis living in western regions
compared to native western populations [10, 11]. The
burden of CHD in Bangladeshis living in western regions is
also higher than that of most other migrant groups, in-
cluding South Asians from India and Pakistan [9]. An
important challenge is, therefore, to establish informative
epidemiological resources in a rigorous yet cost-effective
manner to evaluate risk factors among Bangladeshis.
The present report provides a description of objectives
and methods used in the establishment of the Bangladesh
Risk of Acute Vascular Events (BRAVE) study. It also de-
scribes the baseline characteristics of the study population
recruited so far, and outlines the rationale for the study’s
further development.
Methods
The BRAVE study was established in 2011 by the
Department of Public Health and Primary Care at the
University of Cambridge (the study’s international coor-
dinating centre), in collaboration with the Chronic Non-
communicable Disease Unit at the International Centre for
Diarrhoeal Disease Research, Bangladesh (icddr,b) and the
National Institute of Cardiovascular Disease (NICVD) in
Bangladesh. The icddr,b is the project’s national col-
laborating centre and houses the local laboratory facilities
for the study (Fig. 1). The NICVD, Bangladesh’s largest
cardiology care centre, treats MI patients from Dhaka (the
capital city; population *15 million) as well as from
surrounding semiurban and rural areas.
BRAVE has received approval from the relevant re-
search ethics committee of each of the institutions involved
in participant recruitment. Written informed consent has
been obtained from each participant prior to recruitment,
including for use of stored samples for biochemical, ge-
netic and other analyses. Data collected in this research are
subject to the core data protection principles and require-
ments of the UK Data Protection Act 1998. The investi-
gators and institutional review boards are committed to
ensure that research is conducted according to the latest
version of the Declaration of Helsinki, the Universal
Declaration on the Human Genome and Human Rights
adopted by UNESCO, and other relevant legislation.
Study design and participants
BRAVE is a retrospective case–control study of acute MI
(Fig. 2). Following screening by medically-qualified re-
search officers, patients (male or female; aged at least
20 years) admitted to the emergency rooms of the NICVD
hospital are eligible for inclusion as MI cases if they fulfil
all of the following criteria: (1) presentation at the hospital
within 48 h of the onset of sustained clinical symptoms
suggestive of MI lasting longer than 20 min; (2) presence
of ECG changes indicative of MI (i.e., new pathologic Q
waves, at least 1 mm ST elevation in any 2 or more con-
tiguous limb leads or a new left bundle branch block, or
new persistent ST-T wave changes diagnostic of a non-Q
wave MI); (3) increased cardiac troponin-I (cTnI) levels
[12]; (4) no previous cardiovascular disease, defined as
self-reported history of angina, MI, coronary revascu-
larisation, transient ischaemic attack, stroke, other cardio-
vascular disease or evidence of CHD on prior ECG, or in
other medical records (eTable 1); and (5) not concurrently
hospitalised for any other cardiovascular disease events.
Controls were individuals without a previous self-re-
ported history of cardiovascular disease (as defined above)
drawn from individuals concurrently identified in the same
hospital as index cases, and recruited in the following order
of priority: (1) visitors of patients attending the out-patient
department; (2) visitors of in-patients who are not part of
the BRAVE study; and (3) visitors of index MI cases who
are not their blood relatives. Controls have been recruited
within 48 h of recruiting index cases, and they are ‘‘fre-
quency-matched’’ to cases by sex and age (in 5-year age
bands). Participants have not been enrolled if any of the
following features are evident: (1) a history of acute viral
or bacterial infection in the previous 2 weeks; (2)
documented chronic conditions, such as malignancy, any
chronic infection, leprosy, malaria, tuberculosis or other
bacterial/parasitic infections, chronic inflammatory disor-
ders, chronic hepatitis or chronic kidney disease on past
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medical history; (3) a recent history of any surgery; (4)
pregnancy; or (5) unable to provide consent.
Questionnaire administration and physical
measurements
Research medical officers in BRAVE have administered
pre-piloted epidemiological questionnaires to participants
that sought over 350 items of information in relation to de-
mographic characteristics, lifestyle factors (e.g., tobacco
and alcohol consumption, dietary intake and physical ac-
tivity), personal and family medical history, and medication
usage (Table 1; a copy of the study questionnaire is avail-
able at www.phpc.cam.ac.uk/ceu/research/brave). To col-
lect information on smoking patterns distinctive to South
Asian populations, BRAVE has adapted a population-
specific questionnaire used in other studies of South Asians
[13]. Additionally, a food-frequency questionnaire previ-
ously developed and validated in Bangladesh [14] has been
adapted and further modified for BRAVE (Table 2). This
questionnaire estimates standard portion size assigned to
each food item. Using standardized procedures and equip-
ment; trained research nurses have obtained measurements
of height, weight, waist and hip circumference, systolic and
diastolic blood pressure, and heart rate.Waist circumference
has been assessed over the abdomen at the widest diameter
between the costal margin and the iliac crest, and hip cir-
cumference has been assessed at the level of the greater
trochanters (i.e., the widest diameter around the buttocks).
For both cases and controls, anthropometric measurements
have been performed in a standing position. Study medical
officers have recorded a standard 12-lead ECG.
icddr,b
NICVD
Abbreviations:  icddr,b, International Centre for Diarrhoeal Disease Research, Bangladesh; 
NICVD, National Institute of Cardiovascular Diseases
Fig. 1 Location of the collaborating and recruitment centres in Dhaka
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Data entering, transfer and checking
Two staff involved with data entry, working independently
of each other, have entered into a central database infor-
mation extracted from the questionnaire, physical mea-
surements and ECG recording. Copies of this database
have been held securely, both at icddr,b and at the
Department of Public Health and Primary Care, University
of Cambridge. Access to study data is available only to the
principal investigators and designated data managers
working under their direct supervision. Data have been
transferred monthly to the coordinating centre in Cam-
bridge, UK, where they have been checked for internal
consistency; queries have been referred back for clarifica-
tion to the team based at icddr,b. Computer-generated de-
tailed summary tabulations have been reviewed weekly by
a designated study data manager in Cambridge to help
monitor the study’s progress. Paper copies of completed
questionnaires have been securely stored at the icddr,b.
From mid-2015, data will be collected in a ‘‘paper-less’’
approach that involves electronic data collection using a
bespoke android interface operated through hand-held
tablet devices.
Collection of biological samples
Non-fasting blood samples (with the time since last meal
recorded) have been drawn by trained study staff nurses from
each participant and centrifuged (@10,000 rpm for 10 min)
within45 minof venepuncture. ForMIcases, blood sampling is
conducted within 48 h of the onset of clinical symptoms (time
sinceonset of pain is recorded) andprior to the administrationof
any thrombolytic medication. As the blood sample is typically
obtained fromMI cases while they are in a recumbent position
(e.g., at about 45), the sampling in the controls has also been
carried out in the same manner to limit the possibility of sys-
tematic differences. A total of 24 ml of whole blood has been
drawn from each participant in 2 9 6 ml serum tubes and
2 9 6 ml EDTA tubes (eFigure 1). Isolated serum, EDTA
plasma andwhole blood samples have been transported daily to
the local laboratory where they are stored in cryogenic vials at
-80 C, following temporary storage for few hours at the
laboratory of the recruitment hospital at-40 C. From January
2013, toenail clippings have been taken fromall ten toes of each
participant and initially stored in labelled zip-lock bags at room
temperature. Biological samples have been stored in long-term
repositories in bothCambridge,UK, and inDhaka,Bangladesh.
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Fig. 2 BRAVE study flow diagram of surveillance, enrolment and data collection
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DNA quality and quantification
DNA has been extracted by the Laboratory of the
Government Chemist (LGC) Genomics (Herts, UK) from
whole blood samples using a validated silica-based method
(eFigure 2) [15]. In the initial 6000 extractions (average
yield 100–120 lg per sample), 99.2 % of samples have had
concentrations high enough for genotyping (C50 ng/ll)
and all samples showed 260/280 ratios in the expected
range, indicating that the purity of the extracted DNA is
Table 1 Summary of questionnaire-based information collected
Characteristics Availability of information
Demographic and lifestyle
factors
Age at onset, gender, tobacco use (cigarette or non-cigarette), exposure to environmental tobacco, detailed dietary
habits, and levels of physical activity
Socio economic factors Education, occupation, objects owned, total income, marital status, family size, indoor air pollution, sources of
drinking water
Economic burden of MI Personal cost associated with the current event (treatment and accommodation), source of referral, transportation
costs, costs of attendants, sources of payment
Knowledge and awareness Levels of knowledge and perception of cardiovascular disease, risk factors (such as smoking, diabetes and blood
pressure), prevention and practices would be assessed among controls
Psychosocial factors Stress at work and home, social support, depression and life events; sleeping habits
Women’s health Use of hormonal contraceptives, menstrual and pregnancy history
Medical history Cardiovascular disease, hypertension, diabetes mellitus, atrial fibrillation, cancer, hypercholesterolemia, current
medication use including regularity of antihypertensive intake, other vascular disease, infectious disease, major
surgery and family history
Physical measurements Blood pressure at baseline, heart rate, height, weight, waist and hip circumferences
Coronary assessment Time to initiate thrombolysis, detailed recording of cardiac work-up (e.g. ECG changes/ECHO), reversal of
symptoms and ST segment elevation by[50 % on streptokinase infusion, cardiac marker (Troponin I)
MI Subtype Based on clinical assessment and ECG/ECHO findings subtypes of MI are recorded (such as, anterior, antero-
septal, inferior, lateral, posterior, right ventricle or non ST elevated MI)
Course in hospital and
status
Treatments given, adverse events (if any), outcomes in hospital
ECG electrocardiogram, ECHO echocardiogram, MI myocardial infarction
Table 2 Information collected on dietary intake
Food group Routinely recorded information Relevant key information recorded to reflect local habits
Rice Type and amount of rice Steamed rice (hand pounded) e.g., sada bhat; mixed rice such as biriyani, polau and tehari
Bread Type and numbers of bread
slices
Wheat bread e.g., ruti; recording type flour bread, e.g., chapatti; oil coded, e.g., porotha or
luchi; white bread such as pauruti
Other
carbohydrates
Potato and sugar Consumption of aloo and chini
Meat and
poultry
Chicken, eggs, liver, beef,
mutton, and lamb
Type of chicken, e.g., caged (farmed) or free-range (deshi); method of cooking, e.g.,
grilled or curried
Fish Type and amount of fish Source such as sweet or saline water fish
Dairy Milk, butter and margarine and
other dairy products
Misti (dairy-based dessert); doi (yogurt-based dessert)
Vegetables Types and amount Cooked or raw vegatables; green leafy, yellow, cruciferus, salad vegetable subtypes
Pulses Lentil subtypes Local lentil produce e.g., muger dal, musurir dal, buter dal
Spices Types and amount used in
traditional cooking
Cumin (jeera), Ginger (ada), turmeric (holud) and garlic (roshun)
Fruits Types and amount Seperately for locally grown and imported fruits
Fast foods Types and amount Source (bought or home-made); local recipe (e.g., puri, singara, samosa, kabab) and
Western recipe (e.g., burger, pizza, sandwich, cakes)
Drinks Tea, coffee, soft drinks, alcohol Local beverages such as lassi; local alcoholic preparations; type of sugar-sweetened
beverages, such as carbonated and noncarbonated drinks
Cooking
medium
Cooking oil (recording type)l Common local vegetable oil such as palm oil; refined vegetable oil such as Banaspati or
dalda; purified butter oil (such as ghee); oil purchase circumstance such as bought from
open (unpurified) sources (‘‘khola tel’’) versus as closed container
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high. To minimise systematic biases, stock plates were
generated and have been used to generate plates of DNA
for genotyping, which contain a mixture of cases and
controls along with the negative and positive controls (an
empty well and a sample with known genotype) designed
to address genotyping quality control, plate identification
and orientation. Samples have been genotyped for three
single nucleotide polymorphisms (SNPs) to check DNA
quality and participant sex across all the samples. 100 %
genotyping success rates have been observed and there
have been no gender mismatches, showing that the DNA
extraction, storage, labelling and transport processes al-
ready in place are capable of producing high quality
genetic data.
Initial measurements
For the initial approximately 4000 MI cases and the initial
approximately 4000 controls, total cholesterol and triglyc-
erides have been measured using an enzymatic colorimetric
test (RocheDiagnostic), high-density lipoprotein cholesterol
(HDL-C) has beenmeasured using a homogenous enzymatic
colorimetric assay (Roche Diagnostic HDL-C plus 3rd
generation), and low-density lipoprotein cholesterol (LDL-
C) has been measured using a homogenous enzymatic col-
orimetric assay (Roche Diagnostic LDL-C plus 2nd gen-
eration). All lipid assays have been done with Roche
automated clinical chemistry analyzer (Hitachi 902, Hitachi
Ltd, Tokyo, Japan). For the initial approximately 3000 MI
cases and initial approximately 3000 controls, genotyping
has been done using the ‘‘CardioMetabochip? array’’
(containing *210,000 SNPs) and the ‘‘Exome? array’’
(containing *420,000 single nucleotide variants [SNVs],
mostly low frequency and rare coding variants), both of
which are manufactured by Illumina (San Diego, CA, USA).
The content of these arrays has been described previously
[16, 17]. Pilot studies have commenced to assess arsenic and
other toxic metal (such as lead, cadmium, and copper) in
toenail and whole blood samples using inductively coupled
plasma mass spectrometry [18].
Plans for expansion
By early 2015, the ongoing BRAVE study had recruited over
5000 confirmed first-ever MI cases and 5000 controls. The
main objectives of the study’s next stages are: to expand the
study to 10,000 acuteMI cases and 10,000 controls; to enrich
the bioresource in various ways in order to increase its sci-
entific value; and to accelerate harvesting of its biological
resources (Table 3). Serial blood measurements have been
done within the first 24 h of hospital admission from an
initial 100 acute MI cases, enabling quantification and cor-
rection for potential distortions due to onset acute MI.
Furthermore, serial epidemiological questionnaires, anthro-
pometry, and blood sampling is planned in about 500 par-
ticipants approximately 2–3 years following the initial visit,
enabling quantification of and correction for regression di-
lution [19]. Such re-surveys should help further validate
various questionnaires developed in BRAVE.
Statistical analysis
This report includes analyses for the initial approximately
4500 acute MI cases and 4500 controls, for whom lipid
measurements are available in 4188 cases and 4130 con-
trols. For baseline variables, mean [standard deviation
(SD)] values and frequencies were calculated separately for
MI cases and controls and compared using t test for con-
tinuous variables or Chi-squared test for categorical vari-
ables. Genetic ancestry of the BRAVE participants was
evaluated with principal component analysis, using 19,931
SNPs contained on the Exome? array. SNPs were selected
to have a minor allele frequency[0.05 in South Asians, not
to be in strong linkage disequilibrium (R2\ 0.20) with one
another, and not to relate to known CHD-associated re-
gions [20]. To examine the ancestry of the BRAVE sam-
ples in a global context, 5756 participants in BRAVE and
2504 participants from 26 other populations in the 1000
Genomes project [21] were included in a principal com-
ponent analysis. A South Asian specific principal compo-
nent analysis of BRAVE and the five South Asian
populations from the 1000 Genomes (one of which com-
prises Bengalis from Bangladesh) was also performed.
Analyses were performed using either Stata (version 13,
StataCorp, College Station, TX) or R (http://www.R-pro
ject.org/). Statistical approach for future analyses will be
developed following relevant guideline statements about
reporting standards for observational studies (e.g.,
STROBE [22], NCI/NHGR working group [23]).
Results
For the initial 4500 MI cases and 4500 controls, the mean
delay from blood sample collection (with immediate chil-
ling) to sample separation (with immediate freezing) was
about 15 min. The median (interquartile range) time
recorded between the time of participant’s last meal and
blood collection was 4.2 (2.4–7.3) h. 48 % of participants
reported living in urban areas, and 52 % reported living in
rural areas. 93 % of participants reported being married.
About 35 % of the participants reported having at least
10 years of formal education. The proportion with such
levels of formal education was higher in men than women
(38 vs. 12 %, p\ 0.001), and in people from urban rather
than rural areas (44 vs. 27 %, p\ 0.001).
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The mean age (SD) of MI cases was 53 (10) years.
Almost half (46 %) of the cases were aged 50 or younger.
88 % of the cases were male. The median interval recorded
between the reported onset of MI symptoms and hospital
admission was 5 h. As would be expected, the following
risk factors were more prevalent in cases than controls:
tobacco consumption, history of diabetes and of hyper-
tension, and parental family history of MI. Total and LDL
cholesterol levels were higher in cases than controls,
whereas HDL cholesterol levels were lower in cases than
controls (Table 4).
Comparison with the 1000 Genomes panel of popula-
tions showed that the Bangladeshi population is genetically
distinct from major non-South Asian ethnic groups. This is
suggested by the separate clustering on the scatterplot of
principal components (Fig. 3a). Furthermore, Bangladeshis
clustered distinctly from several other South Asian eth-
nicities in the 1000 Genomes panel (Fig. 3b), and were
perhaps genetically closest to (though still distinct from)
Sri Lankan Tamils.
Discussion
We have established the first large epidemiological biore-
source for the study of MI and related traits in Bangladesh,
demonstrating the feasibility and validity of the study
methods we have used. The initial findings have high-
lighted the striking early-onset nature of MI in Bangladesh,
with nearly half of the cases recruited into BRAVE aged
50 years or younger. The enduring value of large case–
control studies of CHD to investigate genetic and certain
environmental factors has been demonstrated by previous
efforts, such as by the International Studies of Infarct
Survival (ISIS) collaboration (14,000 acute MI cases and
32,000 controls in the UK) [24] and by the INTERHEART
study (15,000 acute MI cases and 15,000 controls from 52
countries) [25].
Until BRAVE, however, the largest study of CHD in
Bangladesh comprised only 228 MI cases and only 238
controls as a component of the INTERHEART study [25].
Furthermore, whereas INTERHEART assessed cardiovas-
cular risk factors common to many countries, the com-
plementary approach in BRAVE has been to focus on these
common risk factors plus a more detailed assessment of
risk factors distinctive to Bangladesh. This focus should
help us to address various unmet strategic needs, such as
those described below.
The first need is to estimate the impact of modifiable
lifestyle factors, since such findings could be of consider-
able relevance to the prevention and control of cardiovas-
cular disease in Bangladesh. For example, little is known
about the relevance to CVD of distinctive and widespread
practices in Bangladesh and other South Asian countries,
such as use of smokeless tobacco (such as jarda or gul) and
different types of oil used in cooking (such as palm oil or
banaspati).
Second, there is a need to determine the relevance to
CHD of arsenic contamination in drinking water in Ban-
gladesh, described by the World Health Organization
(WHO) as ‘‘the largest mass poisoning of a human
population in history’’ [26]. For, in addition to the estab-
lished carcinogenic effects of chronic arsenic exposure,
evidence is emerging of an association between arsenic
exposure and common manifestations of cardiovascular
disease, such as MI [27]. However, studies of arsenic
contamination and CHD in Bangladesh have hitherto been
limited, so far comprising a single report involving only
about 100 CHD outcomes ascertained through verbal au-
topsy [28]. Consequently, it has not been possible to
establish reliably whether or not arsenic exposure is a
causative risk factor for CHD, nor has it been possible to
characterise the shape of any dose–response relationship.
For this reason, the WHO and US Environmental Protec-
tion Agency have stated that cardiovascular disease cannot
be considered a relevant consideration in defining max-
imum arsenic contaminant levels [29]. As a related issue,
there is a need to assess potential joint effects of arsenic
and other metals (such as lead, cadmium, mercury and
copper) on CHD risk. These metals commonly co-occur
Table 3 Biological
measurements planned or in
progress
Approach Analytical strategy
(1) Genomics
CardioMetabochip ? array *210,000 SNPs of interest for cardiovascular disease traits.
Exome ? array *420,000 SNVs, mostly low frequency and rare coding variants
Sequencing High-depth sequencing
(2) Biomarkers
Cardiometabolic analytes Total cholesterol, HDL-C, LDL-C, triglycerides, HbA1c, Lp(a)
Toxic heavy metals Total arsenic, arsenic metabolites, copper, lead, cadmium, and mercury
SNPs single nucleotide polymorphisms, SNVs single nucleotide variants, HDL-C high-density lipoprotein
cholesterol, LDL-C low-density lipoprotein cholesterol, HbA1c haemoglobin A1c, Lp (a) lipoprotein (a)
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with arsenic in groundwater in the deltaic environments of
Bangladesh [30]. Hence, even more powerful studies are
required to study such joint effects reliably than to assess
the relevance to CHD of arsenic alone. We plan, therefore,
to continue expansion of recruitment in BRAVE for some
years and to continue collection of relevant biological
samples (such as toenails and plasma) in order to facilitate
this assessment.
A third need is to create a resource of specific relevance
to people of Bangladeshi ancestry in order to advance
understanding of the genetic determination of CHD and a
variety of related complex traits in this population. In re-
cent years, a limited number of major genetic CHD
bioresources involving (non-Bangladeshi) South Asians
have emerged. Notable examples include the Pakistan Risk
of Myocardial Infarction Study (PROMIS, a study of over
15,000 MI cases and over 15,000 controls in urban Pakistan
[13], led by some of the investigators in BRAVE), and the
London Life Sciences Prospective Population Study
(LOLIPOP, a study of over 3500 CHD cases and over 4000
controls [31], predominantly of Indian and Pakistani des-
cent, living in London, UK). BRAVE complements these
studies by providing a resource of comparable size and
scope in Bangladeshis. Indeed, the results of the principal
component analysis in BRAVE support the suggestion that
Bangladeshis are genetically distinct from the other South
Asian ethnicities. Furthermore, BRAVE complements
studies of Bangladeshis resident in Western countries (such
Table 4 Baseline
characteristics of the initial
participants recruited
Characteristic Cases Controls p value
N Mean (SD) or % N Mean (SD) or %
Age (years) 4500 52.6 (10.4) 4500 50.4 (10.1) Matched
Sex (%)
Males 3950 88 3935 87
Females 550 12 565 13 Matched
Tobacco consumption (%)
Never 630 15 1383 31
Ex 246 6 301 7
Current 3224 79 2811 63 \0.001
History of hypertension (%)
Yes 1090 24 470 10
No 3404 76 4027 90 \0.001
History of diabetes (%)
Yes 778 17 359 8
No 3716 83 4138 92 \0.001
Family history of MI (%)
Yes 597 13 267 6
No/Unknown 3903 87 4233 94 \0.001
Location (%)
Urban 1891 47 2183 49
Rural 2142 53 2282 51 0.065
Level of education reached (%)
No schooling 1390 34 1576 35
Primary 1269 31 1297 29
Secondary 944 23 1107 25
Vocation/University 454 11 518 12 0.093
Blood lipids measurements
Total cholesterol (mmol/l) 4188 5.14 (1.14) 4130 4.77 (1.00) \0.001
LDL-C (mmol/l) 4188 3.19 (1.03) 4128 2.76 (0.86) \0.001
HDL-C (mmol/l) 4188 0.85 (0.22) 4130 0.87 (0.22) \0.001
 p value obtained from t test for continuous variables or Chi squared test for categorical variables.
 Mother and/or father
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, MI myocardial
infarction
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as the recently-launched East London Genes & Health
Study [32], which proposes to involve people of Bangla-
deshi- and Pakistani-origin who live in London and which
aims to recruit participants irrespective of CHD status).
Genetic studies of people of South Asian ancestry
should help to identify both population-specific as well as
genetic risk factors shared by people from different conti-
nental ancestries (‘‘cosmopolitan’’ risk factors). Further-
more, there is evidence to suggest the potential scope for
important ethnic-specific genetic discoveries for cardio-
vascular disease in South Asians. For example, a 25 bp
deletion in MYBPC3 associated with hypertrophic car-
diomyopathy and a sevenfold increase in the risk of heart
failure was discovered in South Asians, whereas it would
have probably remained undetected if studies were con-
fined to other ancestries (since this variant was nearly ab-
sent in the other 20 non-South Asian populations studied
[33]). Additionally, a variant in the SGCG gene has been
associated with type 2 diabetes in Punjabi Sikhs from
northern India, but not with type 2 diabetes in non-South
Asians or with type 2 diabetes in other ethnic groups from
South Asia [34]. The discovery of ethnic-specific genetic
risk factors for Bangladeshis (and, more generally, other
South Asians) should be facilitated by the use of next
generation sequencing technologies. By contrast, the
ability of most previous studies of South Asians to find
population-specific genetic risk factors has been con-
strained by the use of gene arrays based on catalogues of
genetic variation mostly discovered in Europeans, East
Asians, and African Americans. Nevertheless, the use of
such arrays has enabled PROMIS and LOLIPOP to con-
tribute importantly to the discovery of over 25 cos-
mopolitan loci for CHD [17, 35, 36] and type 2 diabetes
[34, 37, 38], showing that there are genetic risk factors for
cardiometabolic conditions that apply to people of South
Asian ancestry and to people of European ancestry.
The strengths and potential limitations of the BRAVE
study merit consideration. Retrospective case–control
studies of MI can usefully complement prospective studies
because the former involve ascertainment of exposure in-
formation and blood sampling of people who have already
developed MI and a comparable group of controls without
MI, which enables rapid and cost-effective accrual of large
numbers of relevant cases, especially in low and middle-
income countries. Furthermore, retrospective studies are
often able to include large numbers of individuals who
have developed the disease at younger ages, when asso-
ciations with risk factors are often stronger. Hence, case–
control studies can provide particularly sensitive tests of
certain hypotheses. As demonstrated by the Wellcome
Fig. 3 Genetic ancestry in the BRAVE population derived from
Principal Component Analysis. The figures above indicate that
Bangladeshis (i.e. the BRAVE study participants and those in the
BEB 1000 Genomes study) cluster separately from major non-South
Asian populations (a) and other South Asian (b) ethnic groups.
BRAVE indicates the Bangladeshis from BRAVE study participants.
The colours of points refer to the self-reported ethnicities in the
BRAVE (n = 5756 and the 1000 Genomes (n = 2504) study
participants: SAN, South Asians; ASN, East Asians; EUR, Euro-
peans; AMR, admixed Americans; AFR, Africans; BEB, Bengalis in
Bangladesh (Non-BRAVE); GIH, Gujrati Indians in Houston, US;
ITU, Indian Telegus in the UK; PJL, Pakistani Punjabis in Pakistan;
STU, Sri Lankan Tamils in the UK. Scatterplot are of the first 2
principal components. C1, first principal component; and C2, second
principal component
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Trust Case–Control Consortium and many subsequent
case–control studies, such studies can powerfully and ef-
ficiently facilitate genetic discovery and can quantify and
robustly correct for any population structure [34–40].
Nevertheless, particularly in relation to non-genetic
hypotheses, retrospective case–control studies may be li-
able to potential biases, such as selection bias, recall bias,
and reverse causality. Hence, following the example of
previous case–control studies of acute MI [13, 24, 25], we
have involved various measures in the current study to help
reduce such potential biases. For example, to reduce the
scope for selection bias, we have sampled controls from
approximately the same source population as the cases. To
reduce the scope for recall bias, we have conducted an
incident case–control study of acute MI and sought infor-
mation from cases within hours of the index event. To
reduce the scope for reverse causality, we intend to focus
efforts on biomarkers not liable to change immediately
after acute MI, such as glycosylated haemoglobin and
lipoprotein (a). We acknowledge that our study may have
limited power to study female-specific associations of risk
factors with MI, as only about 12 % of the MI cases re-
cruited so far have been women.
In conclusion, BRAVE is a large epidemiological
bioresource to investigate the determinants of CHD and of
related traits in Bangladesh. It should help to hasten dis-
covery of disease-causing pathways and to inform appro-
priate disease prevention strategies in Bangladesh and
beyond.
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